ProteoNic's proprietary UNic™ expression enhancement technology enables significant yield improvement in the upstream protein expression. Application has been demonstrated for plant, mammalian (CHO) and fungal host systems. UNic™ is complementary to existing technologies and production elements and implemented in the customers’ manufacturing process, resulting in:
• Increased protein production in the same capacity;
• Faster production and product development;
• Substantial cost reduction.

ProteoNic has closed a number of partnerships with companies in the biopharmaceutical and industrial application markets, a commercial evaluation license (biopharmaceutical) and expects to close a commercial license for the application in a CHO production line shortly.

Speaker Profile

Victor Schut

Victor, co-founder and a lawyer by education, has over 13 years experience as a financial professional mainly active in financing and investing in a wide range of companies as an investor at a Private Equity firm. Victor has been actively involved with a number of companies varying from early stage to expansion of mature businesses. As a “hands on” investor his experience encompasses strategy, finance, management and operations.